Want to see AU:SNT full AI Analyst Report?

Syntara Limited (SNT) Price & Analysis

16 Followers

SNT Stock Chart & Stats

AU$0.03

AU$0.00(0.00%)

At close: Jul 27 4:00 PM EDT

AU$0.03

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.02 - AU$0.04

Previous CloseN/A

Volume167.43K

Average Volume (3M)1.08M

Market Cap

AU$41.25M

Enterprise ValueAU$21.58M

Total Cash (Recent Filing)AU$13.56M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta2.81

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding1,964,519,300

10 Day Avg. Volume1,607,162

30 Day Avg. Volume1,077,841

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)2.06

Price to Sales (P/S)0.00

P/FCF Ratio-3.42

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$0.11

Price Target Upside250.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageA debt-free balance sheet reduces interest obligations and refinancing pressure, preserving flexibility while clinical programs develop. The sizable equity base provides a stronger financial cushion than earlier periods with higher leverage, although it does not yet offset operating losses.

Historical Gross ProfitabilityThe historical gross margin indicates that Syntara’s offerings generated positive economics before operating expenses when revenue was present. If commercial activity returns, this past margin profile could support operating leverage, though current revenue levels do not yet demonstrate that benefit.

Focused Drug-development PlatformA defined amine oxidase platform gives Syntara a focused basis for developing multiple clinical-stage therapies across fibrosis and oncology. Platform-based research can support repeatable scientific development, but its durable value depends on future clinical and commercial validation.

Bears Say

No Recent Revenue ScaleThe absence of reported revenue in the latest two fiscal years shows that Syntara has not yet established a dependable commercial revenue base. This leaves the company’s financial profile dependent on development progress rather than operating scale, increasing uncertainty around future earnings quality.

Persistent Operating LossesContinuing net losses, including a larger FY2026 loss than FY2025, indicate that current operations are not covering the company’s cost base. Without meaningful revenue growth or improved expense absorption, losses can continue to erode equity and constrain investment in the development pipeline.

Sustained Cash BurnNegative operating and free cash flow over several years demonstrates that Syntara is consuming cash to fund ongoing activities rather than generating internal financing. This weakens financial resilience and may require continued use of liquidity or external funding to sustain development programs.

Syntara Limited News

Syntara Expands SNT-9465 Scar Trial as Early SNT-6302 Data Shape Strategy

Syntara Limited ( ($AU:SNT) ) has issued an announcement. Syntara Limited is a clinical-stage biopharmaceutical company developing topical...

4d ago

Syntara boosts R&D funding with A$4.7m tax incentive

The latest announcement is out from Syntara Limited ( ($AU:SNT) ). Syntara Limited has secured an A$4.7 million...

14d ago

Syntara Seeks ASX Quotation for 1.5 Million New Shares

Syntara Limited ( ($AU:SNT) ) has issued an announcement. Syntara Limited has lodged an application with the ASX...

20d ago

Syntara Sets 2026 AGM Date as It Refocuses on Fibrosis and Cancer Pipeline

Syntara Limited ( ($AU:SNT) ) has provided an update. Syntara Limited, an ASX-listed clinical-stage biotechnology company based in...

20d ago

Syntara Loss Widens as Revenue Falls and Asset Base Shrinks

Syntara Limited ( ($AU:SNT) ) has shared an announcement. For the 2026 financial year, Syntara reported a 7.9%...

1M ago

Syntara to Brief Investors on Expanding Clinical Pipeline in Quarterly Webinar

Syntara Limited ( ($AU:SNT) ) has provided an announcement. Syntara Limited will host an investor webinar on 28...

2M ago

Syntara secures FDA backing and funding as key clinical programs advance

Syntara Limited ( ($AU:SNT) ) has provided an announcement. Syntara Limited reported a pivotal June quarter, marked by...

2M ago

Syntara Releases Early Phase 2a Data on SNT-4728 for Sleep Disorder

Syntara Limited ( ($AU:SNT) ) has issued an update. Syntara Limited has released preliminary information on a phase...

3M ago

Syntara reports early Phase 2 evidence of brain inflammation reduction in prodromal Parkinson’s trial

Syntara Limited ( ($AU:SNT) ) has provided an announcement. Syntara Limited has reported preliminary data from a randomised,...

3M ago

Syntara Shares Halted Ahead of Key Parkinson’s Trial Update

Syntara Limited ( ($AU:SNT) ) has shared an announcement. Syntara Limited has requested and been granted a trading...

3M ago

SNT FAQ

What was Pharmaxis Ltd’s price range in the past 12 months?

Pharmaxis Ltd lowest share price was AU$0.02 and its highest was AU$0.04 in the past 12 months.

What is Pharmaxis Ltd’s market cap?

Pharmaxis Ltd’s market cap is AU$41.25M.

When is Pharmaxis Ltd’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Pharmaxis Ltd’s earnings last quarter?

Currently, no data Available

Is Pharmaxis Ltd overvalued?

According to Wall Street analysts Pharmaxis Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pharmaxis Ltd pay dividends?

Pharmaxis Ltd does not currently pay dividends.

What is Pharmaxis Ltd’s EPS estimate?

Pharmaxis Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Pharmaxis Ltd have?

Pharmaxis Ltd has 1,964,519,300 shares outstanding.

What happened to Pharmaxis Ltd’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Pharmaxis Ltd?

Currently, no hedge funds are holding shares in AU:SNT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Syntara Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-10.75%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Pharmaxis Ltd

Syntara Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies by targeting extracellular matrix dysfunction, primarily through amine oxidase chemistry. Headquartered in Frenchs Forest, Australia, the company's research pipeline focuses on blood cancers as well as a range of inflammatory and fibrotic disorders. Its leading investigational compound, amsulostat, is currently in Phase 1c/2 clinical trials for the treatment of myelofibrosis, a bone marrow cancer, and is also being evaluated for myelodysplastic syndrome. Beyond this, Syntara is advancing several other promising drug candidates. These include a suite of topical pan-LOX inhibitors: SNT-9465, which is undergoing Phase 1a/b study for hypertrophic scars, and SNT-6302, designed for keloid scars. Furthermore, SNT-4728 is in development to manage sleep disorders and to potentially slow the progression of neurodegenerative conditions by mitigating neuroinflammation. The company's broader therapeutic ambitions extend to various fibrotic and inflammatory diseases such as kidney fibrosis, MASH (metabolic dysfunction-associated steatohepatitis), pulmonary fibrosis, and cardiac fibrosis. Incorporated in 1998, the company was formerly known as Pharmaxis Ltd before adopting the name Syntara Limited in December 2023.

Syntara Limited (SNT) Earnings & Revenues

Historic Earnings Reports

SNT Stock 12 Month Forecast

Average Price Target

AU$0.11

▲(250.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","-1":"-AU$1","-0.5":"-AU$0.5","0.5":"AU$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$0.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$0.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.06</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.021,0.030923076923076925,0.04084615384615385,0.050769230769230775,0.0606923076923077,0.07061538461538462,0.08053846153846154,0.09046153846153847,0.10038461538461539,0.11030769230769231,0.12023076923076924,0.13015384615384615,0.14007692307692307,{"y":0.15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.021,0.02746153846153846,0.033923076923076924,0.04038461538461538,0.04684615384615384,0.053307692307692306,0.05976923076923077,0.06623076923076923,0.0726923076923077,0.07915384615384616,0.08561538461538462,0.09207692307692308,0.09853846153846153,{"y":0.105,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.021,0.024,0.027,0.03,0.033,0.036,0.039,0.041999999999999996,0.045,0.048,0.051,0.05399999999999999,0.056999999999999995,{"y":0.06,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.028,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.03,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.032,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.035,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.03,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.032,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.032,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.029,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.026,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.021,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.025,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.026,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.021,"date":1790812800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >